Abivax (ABVX) operates in the healthcare sector, focusing on the development of innovative therapies for inflammatory and viral diseases. Its core products include ABX464, aimed at treating ulcerative colitis and HIV. The company primarily generates revenue through research and development partnerships and potential future product sales. Abivax is currently in clinical trial phases, with no commercialized products yet contributing to revenue.
The investment profile of Abivax is more aligned with growth investors, given its focus on developing new therapies and the potential for future revenue generation. However, the high risk associated with its current financial performance and lack of profitability may deter conservative investors. The stock may appeal to those with a higher risk tolerance looking for long-term opportunities.
| Fecha | Antes | Después | Razón |
|---|---|---|---|
| 2026-06-03 02:58 | Mantener | Vender | scenario_deterioration |
| 2026-05-30 02:56 | Vender | Mantener | Weak fundamentals with recent positive momentum. |
| 2026-05-08 15:24 | — | Vender | Weak fundamentals and negative momentum raise significant risks. |
| Fecha | Analista | Acción | Objetivo | Precio entonces |
|---|---|---|---|---|
| 2026-06-03 17:18 | Wolfe Research | Objetivo reducido | 176 → 136 | 89.72 |
| 2026-06-02 12:01 | Truist Financial | Objetivo reducido | 140 → 135 | 77.82 |
| 2026-06-02 11:51 | Morgan Stanley | Objetivo reducido | 145 → 132 | 129.69 |
